Paul Weiss Hires Goodwin Public M&A Co-Head Robert Masella as New York Partner
Robert Masella, a life sciences dealmaker and former Bank of America Merrill Lynch managing director, joins Paul Weiss's M&A group in New York.
Paul, Weiss, Rifkind, Wharton & Garrison LLP said on Monday that Robert F. Masella will join its New York office as a partner in the M&A Group within the Corporate Department. The firm announced the hire in a press release. Law360 reported that Masella co-led Goodwin Procter LLP's public company and life sciences M&A teams. Reuters described him as Goodwin's co-head of public M&A.
Paul Weiss described Masella as a former Bank of America Merrill Lynch managing director. It said he advises public and private companies, corporate boards, private equity funds and financial institutions on domestic and cross-border M&A, with a particular emphasis on life sciences.
Practice and recent work
According to Paul Weiss, his practice covers public and private M&A, dual-track M&A/IPO processes, joint ventures, option agreements, licensing and collaboration agreements, and spin-offs. He also advises boards on corporate governance, shareholder activism, fiduciary duties and conflict-of-interest matters.
The firm listed several recent matters. They include advising SpringWorks Therapeutics on its acquisition by Merck KGaA, Versanis Bio on its acquisition by Eli Lilly, Proteologix on its acquisition by Johnson & Johnson, and Ironshore Therapeutics on its acquisition by Collegium Pharmaceutical. Other clients named were Color Wow (acquired by L'Oréal), Teleflex, Ally Bridge Group and Thomson Reuters.
Goodwin announced in a March 31, 2022 press release that Masella had joined its Mergers & Acquisitions practice and its Life Sciences and Technology groups as a New York partner. The release said he was previously a partner at a major international law firm.
What the firms said
Scott Barshay, chairman of Paul Weiss, said he had worked closely with Masella over many years and called him a "spectacular M&A lawyer and advisor." Krishna Veeraraghavan, global co-head of M&A at Paul Weiss, called Masella a market leader in life sciences. Masella said Paul Weiss's platform and life sciences experience make it "the ideal home for my practice."
What this means for in-house counsel
Lateral moves by senior deal partners can affect conflicts, staffing and pricing on live transactions. If your company uses Goodwin or Paul Weiss on a pending deal, ask your relationship partner whether Masella has had any role on it. Confirm in writing how the move affects team composition. A partner's departure mid-process is a fair moment to ask about continuity and any fee implications.
Lateral moves in general also raise conflicts questions that are worth checking early. A partner who has advised on one side of a sector, such as life sciences, may arrive at a new firm that represents counterparties or competitors. Review your engagement letters and advance waiver provisions. Ask outside counsel how their conflicts teams screen laterals, particularly if you are planning a confidential sale process or a hostile approach in the life sciences sector.
Finally, lateral hiring is a signal of where firms are competing for work. Paul Weiss says Masella has a life sciences emphasis that he "will help drive," which may give companies in that sector one more option when they run a panel review. Use the moment to test your current firms on rates and on the depth of their benches, and to ask who would actually staff your next deal.
Free weekly email
The Counsel House Brief
The week's most important legal news for general counsel and in-house teams, in one short email.
Counsel House corrects errors promptly. Spot one? Email daniel@counselhouse.org.